- 1 Title: A novel time-based surface EMG measure for quantifying hypertonia in paretic arm muscles
- 2 during daily activities after hemiparetic stroke
- 3 Authors: M. Hongchul Sohn^{1,*}, Jasjit Deol^{1,2} and Julius P.A. Dewald^{1,3,4}
- 4 ¹ Department of Physical Therapy and Human Movement Sciences, Feinberg School of Medicine
- 5 Northwestern University, Chicago IL, USA
- 6 ² Neuroscience and Mental Health Institute Graduate Program, University of Alberta, Edmonton
- 7 AB, Canada
- 8 ³ Department of Biomedical Engineering, McCormick School of Engineering, Northwestern
- 9 University, Evanston IL, USA
- 10 ⁴ Department of Physical Medicine and Rehabilitation, Feinberg School of Medicine,
- 11 Northwestern University, Evanston IL, USA
- 12 * Correspondence: <u>hongchul.sohn@northwestern.edu</u>
- 13
- 14 Keywords: EMG; Stroke; Arm Motor Deficit; Remote Monitoring; Home-based Setting

15 ABSTRACT

16 After stroke, paretic arm muscles are constantly exposed to abnormal neural drive from the injured brain. As such, hypertonia, broadly defined as an increase in muscle tone, is prevalent especially 17 18 in distal muscles, which impairs daily function or in long-term leads to a flexed resting posture in 19 the wrist and fingers. However, there currently is no quantitative measure that can reliably track 20 how hypertonia is expressed on daily basis. In this study, we propose a novel time-based surface 21 electromyography (sEMG) measure that can overcome the limitations of the coarse clinical scales 22 often measured in functionally irrelevant context and the magnitude-based sEMG measures that 23 suffer from signal non-stationarity. We postulated that the key to robust quantification of 24 hypertonia is to capture the "true" baseline in sEMG for each measurement session, by which we 25 can define the relative duration of activity over a short time segment continuously tracked in a 26 sliding window fashion. We validate that the proposed measure of sEMG active duration is robust 27 across parameter choices (e.g., sampling rate, window length, threshold criteria), robust against 28 typical noise sources present in paretic muscles (e.g., low signal-to-noise ratio, sporadic motor unit 29 action potentials), and reliable across measurements (e.g., sensors, trials, and days), while 30 providing a continuum of scale over the full magnitude range for each session. Furthermore, sEMG 31 active duration could well characterize the clinically observed differences in hypertonia expressed 32 across different muscles and impairment levels. The proposed measure can be used for continuous 33 and quantitative monitoring of hypertonia during activities of daily living while at home, which 34 will allow for the study of the practical effect of pharmacological and/or physical interventions that try to combat its presence. 35

36 1. INTRODUCTION

Upper extremity motor impairment after stroke is a major contributor to loss of function in daily 37 38 life. Among many neurological conditions that impair control of the paretic arm, hypertonia, 39 broadly defined as an increase in muscle tone, commonly appears in individuals with hemiplegic 40 stroke [1, 2]. Hypertonia is clinically observed to be most prevalent in distal flexor muscles [1, 3, 41 4]. Cumulating evidence suggests that hypertonia present in wrist and finger muscles may be 42 linked to the upregulation of the corticoreticulospinal system following a loss of corticobulbar projections from the lesioned hemisphere [5]. As a result, individuals with severe motor 43 44 impairment after stroke often have difficulties in using their hand, for example, opening the hand 45 or extending the wrist, which is detrimental to many activities of daily living [6]. Studies suggest 46 that prolonged exposure to such abnormal neural drive may further impact musculoskeletal 47 changes in the paretic arm, leading to a flexed resting posture or contractures [7, 8]. Consequently, 48 current treatment of hypertonia largely focuses on wrist/finger and sometimes elbow flexor 49 muscles, which include focal injection of botulinum toxin [9-11], use of wrist/finger orthosis or 50 splints [9, 12, 13], electrical stimulation [14], stretching [15, 16], and surgical procedures such as 51 tendon transfers [17-19].

However, there currently is no quantitative measure that can be used to constantly track how hypertonia is expressed in wrist and fingers muscles, which is crucial for understanding the true impact of hypertonia in daily function or objectively assessing the effectiveness of aforementioned treatments, e.g., pre and post intervention. Hypertonia in clinic is currently assessed using coarse scores such as the Modified Ashworth Scale (MAS) [20-22] and the Modified Tardieu Scale [23]. On the other hand, many studies have also attempted to assess hypertonia more quantitatively using laboratory equipment (e.g., mechatronics combined with dynamometry, 59 sEMG) [16, 24]. However, such momentary measurements which largely relies on manual (in clinics) or instrumented (in laboratory) examination of passive resistance to joint displacement do 60 61 not capture the true presence of hypertonia during daily activities. This is because daily 62 involvement of the paretic arm is most often marked by non-use or neglect, while performing 63 motor tasks with the non-paretic arm or the whole body [25, 26]. As such, there often is not a good 64 correlation between these measures and patient's ratings of abnormal tone experienced daily [11, 65 27, 28], and thus fail to provide useful information about the impact of hypertonia on everyday 66 function.

67 Recent advances in wearable sensors, e.g., inertial measurement unit (IMU) + surface electromyography (sEMG), offer promising avenues to examine motor function of neurologically 68 69 injured individuals in the real-world. As such, they have been employed in many applications in 70 rehabilitation, e.g. to recognize motor pattern or intent for robotic prosthetics control [29-31], to 71 detect disease symptoms or adverse events [32-34], or to provide bio-feedback during training 72 [35]. However, there are remaining gaps in utilizing these technologies to constantly monitor an 73 important neural signature underlying post-stroke motor impairment such as hypertonia. Most 74 importantly, we currently lack a robust measure that can reliably quantify abnormal neural drive 75 to paretic muscles over extended periods of time (e.g., weeks) [36, 37]. In particular, sensitivity 76 of sEMG magnitude to noise and electrode placement makes it challenging to obtain consistent 77 measurements across days [38-40]. For example, measurements via sEMG inherently suffers from nonstationarity of the signal, where magnitude of the signal varies with measurement condition 78 79 such as electrode-skin impedance and electrode location. Further, deficits in stroke survivors to 80 voluntarily activate their muscle raises issues in defining a reference for comparison [41-43].

81 In this study, we propose a novel time-based surface electromyography (sEMG) measure, 82 Active Duration, which can overcome the limitations of the coarse clinical scales often measured in functionally irrelevant context and the challenges associated with magnitude-based sEMG 83 84 measures to quantify hypertonia. We postulate that the key to robust quantification of hypertonia 85 is to capture the "true" baseline in sEMG for each measurement session, by which we can define 86 the length of time (i.e., duration) a muscle is active relative to this baseline using a widely accepted 87 technique for detecting active state of a muscle from sEMG [44-46]. Such approach can be applied 88 over a short time segment tracked in a sliding window fashion to quantify the continuous time-89 course of how and to what extent hypertonia is expressed, e.g., over extended period (hours) during 90 activities of daily living. To validate the robustness of the proposed measure in real-world scenario, 91 we first use sEMG from healthy individuals to test its robustness across parameter choices, against 92 noise, and its reliability across measurements. Further, we demonstrate the feasibility and the 93 utility of the proposed measure with sEMG recorded from paretic arm muscles while individuals 94 with stroke perform various daily activities, such as, while awake, when completely relaxed, as 95 well as during some functional activities such as ambulating in the laboratory. Results are further 96 discussed focusing on the implications to quantifying hypertonia in paretic arm muscles during 97 daily activities after stroke.

98 2. MATERIALS AND METHODS

99 2.1. Active duration: a time-based sEMG measure to quantify hypertonia

Our proposed time-based measure of hypertonia quantifies *Active Duration* of sEMG within a time segment, defined as the percent of time conditioned signal is above a threshold defined with signal distribution. Briefly, the method relies on robust capturing of the "true" baseline in sEMG for each measurement session using an established relaxation protocol (i.e., eliminate hyperactivity) [47, 48], from which we define the relative duration of activity over a short time segment, continuously tracked in a sliding window fashion (Fig. 1A). Specifically, four steps are involved:

Signal pre-processing and conditioning: Raw sEMG recorded from any muscle or channel
 can be pre-processed to first remove any noise known or identified to be present such as
 offset, powerline interference, or substantial motion artifact. Then, the signal is conditioned
 with Teager-Kaiser energy operator (TKEO) to improve signal-to-noise ratio [44-46]:

110 $\Psi[x(n)] = x(n)^2 - x(n+1) \cdot x(n-1),$

111 where x(n) denotes nth sample of the processed sEMG signal. Conditioned sEMG is then112 full-wave rectified.

Defining the segment-based minimum across all recordings (Fig. 1A, top): Processed and
conditioned sEMG is examined with moving average window with a given length (*WL*)
and overlap (in %) to find the minimum (μ) across all recordings for a given muscle. Here, *WL* and overlap are custom parameters that determine the temporal resolution of the final
active duration measure (see section 2.2 below), just as any time-domain smoothing
process would do, which also affects the computational demand (e.g., the smaller the *WL*and greater the overlap, the greater the demand).

3) Defining the threshold criteria (Fig. 1A, middle): For the segment where minimum mean
(μ) was found above, standard deviation (σ) is calculated. The threshold criterion (*TC*) for
defining active state of a muscle is defined as:

123 $TC = \mu + N\sigma,$

124 where N is the multiplication factor, which is a widely used method for detecting the onset 125 in sEMG signals [44-46]. This factor N determines the sensitivity in detecting an active 126 state, where ranges of numbers have been used or tested in literature [44-46], e.g., 1-3 and 3-23 for sEMG without and with TKEO conditioning, respectively. For the proposed 127 128 measure active duration, TC determines the lower bound and the relative mapping to the 129 signal magnitude (see section 2.2. below). While larger TC (e.g., μ +8 σ) is often used to 130 detect EMG onset during voluntary movements in healthy individuals [44-46], for paretic 131 muscles where signal-to-noise ratio (SNR) is often expected to be very low [49, 50], 132 smaller TC (e.g., μ +3 σ) is recommended to more robustly capture the hyperactive muscle 133 tone.

4) Active duration calculation (Fig. 1A, bottom): Once *TC* is defined from the previous step,
this can be used to count, on segment basis (window length: *WL*), the number of datapoints
that are above the threshold in percentage of time.

Results from segments in consideration can be then used to construct a continuous, time-course of active duration of sEMG, at given temporal resolution as determined by *WL* and overlap, where a different overlap interval can be used than in step 2), depending on the purpose. For example, one may choose to use greater overlap for more smooth and continuous visualization, whereas use results with no overlap to ensure statistical independence in analyzing time-series data [51]. An example with WL=5 s and N=3 (i.e., $TC=\mu+3\sigma$) shows, active duration over 60 s when an individual with stroke was performing various activities of daily living (see section 2.3 for detail).

145 2.2. Validating robustness and reliability of active duration measure

To validate the sEMG active duration as a useful and reliable measure for daily monitoring or tracking of hypertonia in home-based setting, we first used experimental data from healthy individuals to systematically examine the sensitivity of sEMG active duration in detecting neural drive to muscles and quantifying the degree in relation to signal magnitude (or power). Specifically, we assessed the robustness of the proposed measure across parameter choices and against simulated noise, and its reliability across measurements conditions.

152 2.2.1. Experimental protocol and setup

Total six healthy young adults (age 24-29 years; 3 females) participated. All participants gave
informed consent prior to the experiment. All procedures and protocols were approved by the
Northwestern University Institutional Review Board.

Participants completed two sessions, apart by a week on average (6.8±4.3 days), repeating the same protocol. Each day (session), participants performed series of motor tasks mimicking activities of daily living (ADL). While we ultimately seek to apply the method during any ADL, for validation purposes here, we used standardized protocols that closely mimic ADL and represent typical states of daily arm involvement and engaging sub-maximal level of muscle activation in a controlled way.

• Baseline: This task represented a completely *relaxed* state, e.g., when a participant is asleep/nearly asleep, where in the case of individuals with stroke, abnormal tone or hypertonia is expected not to be present, providing a "true" baseline. For healthy individuals, however, complete relaxation is readily achievable. During baseline,
 participants were seated on a standard chair with arm naturally supported on laps for 2.5
 minutes.

- Timed Up and Go (TUG): This task represented the *ambulatory* state which involves a functional, whole-body movement. TUG is a clinical test designed to assess basic mobility in neurologically impaired individuals [52, 53]. The test is comprised of a sequence of functional maneuvers including rising from a chair (at the verbal cue 'Go'), walking 3 meters (distance indicated by a line on floor to cross), walking back, and sitting down again. In the case of individuals with hemiparetic stroke, participants are allowed to use customary walking aids (e.g., cane) used in daily living.
- 175 Timed Dumbbell (TD): This task is designed to have participants activate different groups • of muscles at a controlled level, while performing a set of isotonic dumbbell-lifting (3 176 177 different weights) with their dominant (right) arm in a standardized manner, synchronized 178 to a digital metronome with visual and audio feedback in real time. The 3 set of weights 179 were selected for each participant, prior to the actual experiment, at levels that will engage 180 at least perceivable effort but not inducing any fatigue and was used consistently across the 181 two sessions for each participant. The TD tasks targeted various Degrees of Freedom 182 (DoF), including wrist flexion/extension (WF/WE), elbow flexion/extension (EF/EE), and 183 shoulder abduction (ABD), each repeated 7 times (see Table 1. for detailed procedure).

Maximum Voluntary Contraction (MVC): MVCs for wrist flexion/extension (WF/WE),
 elbow flexion/extension (EF/EE), and shoulder abduction (ABD) were performed to
 capture the maximum level of voluntary muscle activation for each session. To control for
 consistent posture across sessions and provide support (restraint) for engaging maximal

188 effort, participants were seated on the Biodex chair (Biodex Medical Systems, Inc., Shirley, 189 New York, USA), with apertures fixed at similar range across participants while 190 accommodating for each participant's comfort (Fig. 2B), which was kept consistent across 191 sessions. MVC trial for each DoF lasted about 5 s each, encouraged by verbal stimuli, and 192 were repeated 3 times, with sufficient breaks in between.

All procedures were instructed and administered by the same licensed physical therapist to
 ensure consistency and repeatability.

Participants repeated the sequence of Baseline, TUG, and TD three times, with consecutively increasing weights in the TD tasks. MVC trials were completed at the end of the experiment. This order was devised to minimize the influence of potential fatigue, which was also monitored through verbal communication with the participant.

199 During each trial in all sessions, muscle activity was recorded at 2 kHz from the given set of 200 target muscles across the wrist/finger, elbow, and shoulder joints (see Fig. 2 and Table 1 for 201 detailed list and abbreviations) from the dominant (right) arm using a wireless sEMG system 202 (Delsys Trigno[™], Delsys, Natick, MA). Raw sEMG signals were manually inspected to remove 203 any artifact or noise including powerline interference in a consistent manner using an auto-204 regression modeling [54] and a spectral interpolation technique [55]. In addition, tri-axial 205 acceleration and angular rate were recorded (148.148 Hz, synchronize with sEMG signal at 2:27 206 ratio) with inertial measurement unit (IMU) sensors attached at the trunk (sternum), elbow 207 (proximal to olecranon fossa), and forearm (ulnar-radial styloid) (Fig. 2). IMU signals were further 208 low-pass filtered with zero-phase Butterworth filter (4th order) at 10 Hz cut-off frequency, which 209 were used to detect and segment sEMG data according to each task.

Between the two sessions, two different sets of sensor elements were used (assigned in random order across participants) to incorporate potential differences between elements/channels, in addition to natural inter-day variability across measurement days (see section 2.2.4).

213

214 2.2.2. Robustness across parameter choices

Ranges of selected parameters involved in calculation of sEMG active duration (see section 2.1.) were tested. First, to examine the effect of window length (*WL*), which determines the temporal resolution of resulting active duration calculated, we tested *WL* of 0.5, 1, 2, and 5 s. This parameter can be also customized depending on the type of task being examine, e.g., slow/static vs. fast/dynamic, or computational demand such as memory and data storage size.

To emulate different sensor specification and re-sampling processes that may be potentially used, we tested sampling rates of 200 Hz, 400 Hz, 1kHz, and 2 kHz by decimating (with lowpass Chebyshev Type I infinite impulse response filter of order 8, to prevent aliasing during downsampling) at ratio 1/10, 1/5, 1/2, and 1 of the original signal at 2 kHz, respectively.

To examine the effect of threshold criteria (*TC*) that defines the active state of a muscle, we tested the multiplication factor N (where $TC = \mu + N\sigma$) of 2, 3, 5, and 10.

In all cases, when the parameter of interest was systematically varied, other parameters were kept constant, which were selected as WL=2 s, sampling rate = 2 kHz, and N=3 as default.

Finally, we were also interested in investigating the relationship between the proposed measure and the magnitude (or power) of the signal, we examined the shape of the one-to-one mapping between the sEMG active duration and root mean square (RMS) calculated with corresponding parameter (s) on segment basis. Specifically, the initial slope (at low level) and the minimum offset of this curve was used to determine the sensitivity and consistency of sEMG active duration in detecting the onset state of a muscle, respectively. On the other hand, the range spanned and the general shape from minimum to maximum value was used to determine the extent to which and how sEMG active duration spanned the range of magnitudes (i.e., RMS).

236

237 2.2.3. Robustness against simulated noises

238 Because our method is targeted to quantify the sEMG active duration in paretic muscles, where 239 low SNR (i.e., due to paresis and deficit in voluntary activation [41-43]) and presence of abnormal 240 neural drive (e.g., involuntary, sporadic firing [56]) are expected, we emulated such conditions by 241 injecting simulated noise to the sEMG recorded from healthy individuals. In particular, we tested 242 robustness of resulting sEMG active duration against two types of noise. First, we simulated 243 overall increased background noise level in a muscle or a channel by injecting gaussian white noise 244 with varying SNR 1, 2, 5, 10, and 20 dB, generated with built-in function 'awgn.m' in Matlab 245 (Mathworks, Natick, MA), in which the power of the input (clean) signal is estimated using the 246 data from representative trials of each type concatenated for each muscle/channel.

247 In addition, to model the sporadic motor unit firing patterns with varying statistical 248 characteristics, we employed the model developed by Konstantin et al., [57], where parameters 249 were modified for muscles and the sEMG data examined in this study. Briefly, the model allows 250 for simulating synthesized sEMG signals mainly driven by the excitation profile for the motor 251 neuronal pool, while incorporating realistic motor neuron behavior, muscle fiber innervation 252 geometry, and tetanic force development [57]. Specifically, to test whether sEMG active duration 253 has the sensitivity to capture the statistical characteristics of motor unit action potential, we used 254 two types of excitation profiles (Fig. 4B, in section 3): trapezoid (15s ramp up - 15 s hold - 15s 255 ramp down) and constant with varying firing rate (at default, 1/2, and 1/5 frequency). The

synthesized EMGs were then superimposed onto the experimental sEMG data from the Baselinetrials, to calculate the resulting active duration.

258

259 2.2.4. Reliability across measurements

260 Finally, we tested the reliability of sEMG active duration measured between two different sessions, 261 naturally affected by inter-day variability and different set of sensor elements within an individual. 262 Reliability was assessed with an intraclass correlation coefficient (ICC, excellent when ≥ 0.90 , 263 good when $0.75 \le ICC < 0.90$, moderate when $0.50 \le ICC < 0.75$, and poor when ICC < 0.50 [58]), 264 where 3 repetitions for each type of task in each day were considered as random effect. To this 265 end, data from each task type was segmented to consistent length and aligned in time (using IMU 266 signals) between the two days, which encapsulated the main task in the middle. Selected lengths 267 for Baseline, TUG, TD, and MVC trials were 65, 35, 103, and 20 s, respectively.

268

269 2.3. Demonstrating feasibility and utility in paretic muscles

270 2.3.1. Experimental protocol and setup

Total three individuals with chronic hemiparetic stroke (22.0±10.5 years post stroke; age 62.7±7.5; 272 2 females) participated. We recruited participants who had varying levels of motor impairment, as 273 assessed by Fugl-Meyer Assessment upper extremity portion (FMA-UE) [61], with scores apart 274 by minimal clinically important differences [59]. All participants gave informed consent prior to 275 the experiment. All procedures and protocols were approved by the Northwestern University 276 Institutional Review Board.

277 Participants performed daily motor tasks similar to the previously described protocol (in 278 section 2.2). However, to distinguish the baseline state when hypertonia is present or absent, we 279 used three different states. *Relaxed* state represents when participant is asleep/nearly asleep. 280 Following an established protocol to maximally relax paretic muscles [60], participants sat 281 comfortably on a supported/reclined chair in a dark quiet room with relaxing musing for 15 282 minutes. Awake state represents sedentary [61, 62], yet awake condition with paretic arm at rest. 283 Participants were seated on a standard chair with paretic arm naturally supported. Ambulatory state 284 represents involvement of the paretic arm during whole-body, functional task. Participants 285 performed the TUG test, as described before. While MVC were collected for reference, data from 286 these trials were not included in the analysis (see below) because individuals have difficulty in 287 voluntarily activating the muscles, especially with more severe motor impairments [41-43]. 288 Indeed, it was found that the magnitude of muscle activity in some participants were greater when 289 involuntary drive was present than those observed during the MVC trials. All procedures, 290 including the clinical test (FMA-UE) were administered by licensed physical therapist.

During the experiment, sEMG and IMU data were collected as previously described, however, using a subset of muscles for sEMG, excluding the three shoulder muscles as hypertonia is less prevalent in these proximal muscles.

294

295 2.3.2. Analysis

Our main focus was to test whether the proposed measure sEMG active duration can characterize the clinically observed differences in hypertonia expressed across different muscles and impairment levels well. Specifically, based on the well-known clinical observations and findings on prevalence of hypertonia [1, 3, 4], we hypothesized that active duration is greater in distal, than in proximal muscles, and increases with the severity of impairment level. To test this hypothesis, we used a linear mixed-effects model with active duration as dependent variable, and state (3

- 302 levels: *Relaxed*, *Awake*, and *Ambulatory*; see section 2.3.1), joint (2 levels: distal, proximal), and
- 303 impairment level (i.e., FMA-UE) as fixed effects, and subject and muscle as random effects.

304 **3. RESULTS AND DISCUSSIONS**

305 3.1. Validation of sEMG active duration measure

For brevity and clarity, here we report and discuss only the examples from a representative participant and muscle TRI. Nevertheless, results were consistent across all muscles and all participants. All data and codes are available upon proper request to the corresponding author.

309 3.1.1. Robustness across parameter choices

310 We found that the proposed measure was robust across parameter choices (Fig. 3). For example, 311 using larger window length had smoothing effect, as would be expected for magnitude-based 312 measure such as RMS (Fig. 3A, top left two). In relation to magnitude (Fig. 3A, right), RMS 313 normalized to 100% at MVC, sEMG active duration sensitively (i.e., sharp initial slope) and 314 robustly (i.e., consistent minimum offset) captured the active state of a muscle, lateral head of the 315 triceps (TRI) in this case, while still providing a continuum of scale over the full magnitude range 316 (i.e., range span from near-zero to 100%) in a nonlinear fashion, which asymptotically saturates at 317 ~25% RMS, however with a clearly distinguishable curve even beyond.

Testing across range of other parameters, such as sampling rate (Fig. 3B) and threshold criteria (Fig. 3B), also demonstrated that the method may allow for parameter optimization among various sensor configurations and tasks.

Robustness of the proposed measure sEMG active duration across ranges of various parameters confer reliable quantification of hypertonia across time, at both spatial and temporal resolution far exceeding the current, momentary measures in clinic- [20-22] or laboratory-based settings [16, 24]. Moreover, wider range of possible sEMG sensor configuration, e.g., low sampling rate, will allow for the use of more power-efficient sensor systems, that are more well-suited for real-world deployment, e.g., for daily use at home, outside the laboratory [32-34]. 327

328 3.1.2. Robustness against simulated noise sources

329 In addition, the proposed measure was robust against typical noise sources present in paretic 330 muscles. When contaminated with gaussian white noise with varying SNR, the sEMG active 331 duration could still sensitively and robustly capture active state of a muscle (Fig. 4A, left). In the 332 case of RMS, in contrast, much of the signal was buried with low SNR (Fig. 4A, middle), which 333 would be problematic especially when applied to muscles with substantial paresis [41-43]. 334 Relationship to magnitude became more linear and spanned lesser range with lower SNR, however 335 while still providing a continuum of scale that can be mapped to 0 to 100% RMS (Fig. 4A, right). 336 When we simulated noise that mimic sporadic motor neuron action potentials often observed 337 in a paretic muscle, the change in temporal profile of the sEMG active duration from Baseline 338 closely followed the excitation profile, and thus the statistical characteristics of motor unit firing 339 or recruitment (Fig. 4B, right). The magnitude-based measure RMS, on the other hand, rather 340 represented the amplitude of the injected noise (Fig. 4B, left), indicating that it will be subjected 341 to ignoring the low-level manifestation of hypertonia as small offset (or noise) in background.

342 While pathological pattern of muscle activity has been often considered as noise or practical 343 barriers in using magnitude-based sEMS measures [63, 64], our results suggest that sEMG active 344 duration may be useful for examining important neuropathological characteristics of paretic 345 muscle recruitment. Increased involuntary muscle tone (i.e., hypertonia) makes limb movement 346 difficult and is influenced by the need/demand/intention to use the paretic/nonparetic limb or the 347 whole body [65-67]. Evidence further suggests that the same neural mechanism, upregulation of 348 corticoreticulospinal system due to the lost corticofugal projections [68-70], underlies the 349 manifestation of abnormal drive to paretic muscles in various forms, resulting in the expression of the flexion synergy [71-73], spasticity [74], associated reactions [75], paresis (resulting in 'learned non-use' [76]) and associated functional motor deficits. Thus, provided with the exact real-world context in which such deficits are experienced and manifested, the sEMG active duration can be a useful measure to probe into the true impact of abnormal neural drive and resulting motor impairments during activities of daily living.

355

356 3.1.3. Reliability across measurements

357 Finally, we also found that the proposed measure sEMG active duration is reliable across 358 measurements, i.e., repetitions within a day as well as across days. For example, the time trace of 359 3 repetitions of the same task in the same session for each Day 1 (Fig. 5A, left) and Day 2 (Fig. 360 5A, right) were highly repeatable, both within days as well as across days. Inter-day reliability of 361 sEMG active duration was also excellent, resulting in intra-class correlation coefficient over 0.99 362 in most muscles examined (Fig. 5B). Especially, the near-zero% value at the Baseline and near-363 100% value at MVC were very consistent, which was the case for all muscles and individuals. 364 This result indicates that the measure (e.g., with default parameters selected in this study) provides 365 highly reliable and consistent lower and upper bounds that is comparable across muscles and 366 individuals, in stark contrast to magnitude-based sEMG measures that suffer from normalization 367 issues [41-43].

Furthermore, such high reliability across measurement days suggest that the sEMG active duration can be a solution to the remaining challenges in using sEMG signal to obtain robust measurements over extended period of time, e.g. across days or weeks [36, 37].

371

372 **3.2.** Feasibility and utility in paretic muscle: preliminary results

373 Our preliminary results (n=3) demonstrate that the proposed, time-based measure sEMG active 374 duration can well characterize the clinically observed differences in hypertonia expressed across 375 different muscles and impairment levels (Fig. 6). Using this measure, we found that hypertonia 376 was more prevalent (i.e., active for longer duration) in distal wrist/finger muscles than proximal 377 elbow muscles during Awake ($t_{254}=5.45$, p<10⁻⁶) and Ambulatory states ($t_{282}=3.54$, p<0.001). 378 Importantly, however, there was no difference across muscles ($t_{254}=0.99$, p=0.32) or subjects 379 (insignificant random effect) during completely Relaxed state (Fig. 6A), indicating that our 380 relaxation protocol [60] successfully quieted all muscles, and that our measure robustly quantifies 381 the "true" baseline that is consistent/comparable across muscles and subjects, which was not the 382 case with magnitude-based measures (e.g., RMS, normalized to MVCs). Furthermore, the amount 383 of reduction in active duration from Awake to Relaxed state, i.e., difference between "nominal" 384 and "true" baseline, increased as a function of impairment level (FMA-UE), more so in distal 385 muscles (Fig. 6B; t_{254} =-3.51, p<0.001), indicating that individuals with more severe impairment 386 would experience a longer period of continuous involuntary activity, especially in the distal 387 muscles, even during an ordinary resting state while awake.

388 4. CONCLUSIONS

389 Here, we presented the work aimed at developing a time-based surface EMG measure that can be 390 used to track stroke-induced hypertonia during activities of daily living. We validated that the 391 sEMG active duration measure is robust across parameter choices (e.g., sampling rate, window 392 length, threshold criteria), robust against typical noise sources present in paretic muscles (e.g., low 393 signal-to-noise ratio, sporadic motor unit action potentials), and reliable across measurements 394 (e.g., sensors, trials, and days), while providing a continuum of scale over the full magnitude range 395 for each session. Furthermore, sEMG active duration could well characterize the clinically 396 observed differences in hypertonia expressed across different muscles and impairment levels. 397 Taken together, this novel time-based measure is well-suited for continuous and quantitative 398 monitoring of hypertonia in the real-world, e.g., while at home, when integrated with commercially 399 available wearable sensors that are easy-to-use (easy-to-"don and dof" and "wear") [77]. Such a 400 monitoring system will allow for the study of practical effect of pharmacological and/or physical 401 interventions and facilitate the investigation of daily impact of hypertonia and its underlying neural 402 mechanisms.





Figure 1. Proposed time-based sEMG measure: Active duration. (A) Conditioned sEMG is examined with a moving average window (e.g., 5 s) to find the minimum across all recordings (top), from which a threshold of active state was defined (middle). Active duration is calculated for each segment as the percent of time amplitude was above the threshold (bottom). (B) Time trace of conditioned sEMG and calculated active duration (bottom) over 60 s from a representative participant with stroke during normal *Awake*, completely *Relaxed*, and functional *Ambulatory* states.




411

412 **Figure 2.** Sensor placement. Muscle activity (sEMG) was recorded from 3 shoulder (orange), 2

413 elbow (red), and 6 wrist/hand (purple) muscles. IMU data was recorded from two locations (trunk

414 and wrist) to monitor gross movement and to segment sEMG data based on event detection.



416 Figure 3. Robustness across parameter choices. (A) Resulting sEMG active duration (left) and 417 corresponding RMS (middle) for various motor tasks, when window length is systematically 418 varied. The relationship between active duration and RMS represented as the one-to-one mapping 419 of active duration and RMS on segment basis (right). (B) Resulting sEMG active duration when 420 sampling rate is systematically varied. (C) Resulting sEMG active duration when threshold criteria 421 are systematically varied.




Figure 4. Robustness against simulated noise sources. (A) Resulting sEMG active duration (left)
and corresponding RMS (middle) for various motor tasks, when background noise with varying
signal-to-noise ratios (SNR) are added. The relationship between active duration and RMS (right).
(B) Resulting sEMG active duration (left) and corresponding RMS (right), when simulated EMG
with sporadic motor unit action potentials with varying statistical characteristics (top) are added to
sEMG during baseline.





Figure 5. Reliability across measurements. (A) Active duration calculated for various tasks during three repetitions within a day, and across two sessions Day 1 (left) and Day 2 (right), that was apart by 3 days. Error bars indicate standard error (SE). (B) Inter-day reliability, as measured by intraclass correlation coefficient (ICC). (C) ICC for other four muscles for the same representative participant are displayed.



435

Figure 6. Preliminary results with individuals with stroke (n=3), with varying level of impairment
(FMA-UE). (A) Comparison of sEMG active duration between distal wrist and proximal elbow
muscles during *Awake*, *Relaxed*, and *Ambulatory* states. Each data point indicates mean±SE across
12 segments for each muscle in each state. (B) Amount of reduced time active in *Relaxed* relative
to *Awake* state, as a function of impairment level (FMA-UE).

Joints	Muscles	Abbrev.
Wrist	Flexor carpi radialis	FCR
	Flexor digitorum superficialis	FDS
	Flexor carpi ulnaris	FCU
	Extensor carpi radialis	ECR
	Extensor digitorum communis	EDC
	Extensor carpi ulnaris	ECU
Elbow	Biceps brachii	BIC
	Triceps brachii lateral head	TRI
Shoulder	Anterior deltoid	AD
	Middle deltoid	MD
	Posterior deltoid	PD

 Table 1. Target muscle list for sEMG recording

DoF	TD task procedure*	
Wrist flexion (WF)	Upper arm on side, elbow 90°, forearm supinated with palm facing superior (up), begin	
	from fully down (extended), 7 cycles of down-up-down at 90 BPM**	
Wrist extension (WE)	Upper arm on side, elbow 90°, forearm pronated with palm facing inferior (down)	
	begin from fully down (flexed), 7 cycles of down-up-down at 90 BPM	
Elbow flexion (EF)	Upper arm on side, forearm supinated with palm facing anterior, begin from elbow	
	fully extended (0°), 7 cycles of elbow 0°-150° (fully flexed)-0° at 70 BPM	
Elbow extension (EE)	Upper arm raised on side, forearm pronated with palm facing anterior, begin from	
	elbow fully extended (0°), 7 cycles of elbow 0°-150° (fully flexed, behind the head)	
	0° at 70 BPM	
Shoulder abduction (Abd)	Begin from arm on side, forearm in neutral with palm facing medial, keep elbow full	
	extended (0°) and forearm neutral, 7 cycles of shoulder 0°-90° (prior to elevation)-0°	
	abduction at 70 BPM	

 Table 2. Description of detailed protocols for each DoF

** In all cases, participants were instructed to "use only as much effort needed".

* BPM: bit per minute.

442

- 443 Supplementary Materials: N/A.
- 444 Author Contributions: Conceptualization, M.H.S.; methodology, M.H.S. and J.D.; software,
- 445 M.H.S.; validation, M.H.S. and J.P.A.D.; formal analysis, M.H.S.; investigation, M.H.S. and J.D.;
- 446 resources, J.P.A.D.; data curation, M.H.S.; writing—original draft preparation, M.H.S.; writing—
- 447 review and editing, M.H.S, J.D., and J.P.A.D.; visualization, M.H.S.; supervision, M.H.S. and
- 448 J.P.A.D.; project administration, J.D. and J.P.A.D.; funding acquisition, J.P.A.D. All authors have
- 449 read and agreed to the published version of the manuscript.
- 450 Funding: This research was funded by Department funds to M.H.S. and J.D., the NIH
- 451 R01NS105759 to J.P.A.D. and the NIHR01HD084009 to J.P.A.D. and W.M.M
- 452 Institutional Review Board Statement: Not applicable.
- 453 **Data Availability Statement:** All data and codes used in this paper are available on proper request
- 454 to the corresponding author: <u>hogchul.sohn@northwestern.edu</u>.
- 455 Acknowledgments: Any support given which is not covered by the author contribution or funding
- 456 sections, e.g., administrative and technical support, or donations in kind.
- 457 **Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the
- 458 design of the study; in the collection, analyses, or interpretation of data; in the writing of the
- 459 manuscript, or in the decision to publish the results.

460 **REFERENCES**

- 461 1. Marciniak, C. "Poststroke Hypertonicity: Upper Limb Assessment and Treatment." *Top*462 *Stroke Rehabil* 18, no. 3 (2011): 179-94.
- 463 2. Sheean, G., and J. R. McGuire. "Spastic Hypertonia and Movement Disorders:
 464 Pathophysiology, Clinical Presentation, and Quantification." *PM R* 1, no. 9 (2009): 827465 33.
- 466 3. Li, S., D. G. Kamper, and W. Z. Rymer. "Effects of Changing Wrist Positions on Finger
 467 Flexor Hypertonia in Stroke Survivors." *Muscle Nerve* 33, no. 2 (2006): 183-90.
- 468 4. Twitchell, T. E. "The Restoration of Motor Function Following Hemiplegia in Man." *Brain*469 74, no. 4 (1951): 443-80.
- 470 5. McPherson, J. G., M. D. Ellis, C. J. Heckman, and J. P. Dewald. "Evidence for Increased
 471 Activation of Persistent Inward Currents in Individuals with Chronic Hemiparetic Stroke."
 472 J Neurophysiol 100, no. 6 (2008): 3236-43.
- Broeks, J. G., G. J. Lankhorst, K. Rumping, and A. J. Prevo. "The Long-Term Outcome of Arm Function after Stroke: Results of a Follow-up Study." *Disabil Rehabil* 21, no. 8 (1999): 357-64.
- 476 7. Metoki, N., Y. Sato, K. Satoh, K. Okumura, and J. Iwamoto. "Muscular Atrophy in the
 477 Hemiplegic Thigh in Patients after Stroke." *Am J Phys Med Rehabil* 82, no. 11 (2003):
 478 862-5.
- 479 8. O'Dwyer, N. J., L. Ada, and P. D. Neilson. "Spasticity and Muscle Contracture Following
 480 Stroke." *Brain* 119 (Pt 5) (1996): 1737-49.
- 481 9. Yasar, E., F. Tok, I. Safaz, B. Balaban, B. Yilmaz, and R. Alaca. "The Efficacy of Serial Casting after Botulinum Toxin Type a Injection in Improving Equinovarus Deformity in Patients with Chronic Stroke." *Brain Inj* 24, no. 5 (2010): 736-9.
- Bakheit, A. M., A. F. Thilmann, A. B. Ward, W. Poewe, J. Wissel, J. Muller, R. Benecke,
 C. Collin, F. Muller, C. D. Ward, and C. Neumann. "A Randomized, Double-Blind,
 Placebo-Controlled, Dose-Ranging Study to Compare the Efficacy and Safety of Three
 Doses of Botulinum Toxin Type a (Dysport) with Placebo in Upper Limb Spasticity after
 Stroke." *Stroke* 31, no. 10 (2000): 2402-6.
- Simpson, D. M., D. N. Alexander, C. F. O'Brien, M. Tagliati, A. S. Aswad, J. M. Leon, J.
 Gibson, J. M. Mordaunt, and E. P. Monaghan. "Botulinum Toxin Type a in the Treatment of Upper Extremity Spasticity: A Randomized, Double-Blind, Placebo-Controlled Trial." *Neurology* 46, no. 5 (1996): 1306-10.
- Popovic, D., A. Stojanovic, A. Pjanovic, S. Radosavljevic, M. Popovic, S. Jovic, and D.
 Vulovic. "Clinical Evaluation of the Bionic Glove." *Arch Phys Med Rehabil* 80, no. 3 (1999): 299-304.
- 496 13. Doucet, B. M., and J. A. Mettler. "Effects of a Dynamic Progressive Orthotic Intervention 497 for Chronic Hemiplegia: A Case Series." *J Hand Ther* 26, no. 2 (2013): 139-46; quiz 47.
- Leung, J., L. A. Harvey, A. M. Moseley, C. Tse, J. Bryant, S. Wyndham, and S. Barry.
 "Electrical Stimulation and Splinting Were Not Clearly More Effective Than Splinting Alone for Contracture Management after Acquired Brain Injury: A Randomised Trial." J *Physiother* 58, no. 4 (2012): 231-40.
- 502 15. Selles, R. W., X. Li, F. Lin, S. G. Chung, E. J. Roth, and L. Q. Zhang. "Feedback503 Controlled and Programmed Stretching of the Ankle Plantarflexors and Dorsiflexors in

- 504Stroke: Effects of a 4-Week Intervention Program." Arch Phys Med Rehabil 86, no. 12505(2005): 2330-6.
- 506 16. Yeh, C. Y., J. J. Chen, and K. H. Tsai. "Quantifying the Effectiveness of the Sustained
 507 Muscle Stretching Treatments in Stroke Patients with Ankle Hypertonia." *J Electromyogr*508 *Kinesiol* 17, no. 4 (2007): 453-61.
- Peraut, E., L. Taieb, C. Jourdan, F. Coroian, I. Laffont, M. Chammas, and B. Coulet.
 "Results and Complications of Superficialis-to-Profundus Tendon Transfer in Brain-Damaged Patients, a Series of 26 Patients." *Orthop Traumatol Surg Res* 104, no. 1 (2018): 121-26.
- 513 18. Keenan, M. A., J. I. Korchek, M. J. Botte, C. W. Smith, and D. E. Garland. "Results of
 514 Transfer of the Flexor Digitorum Superficialis Tendons to the Flexor Digitorum Profundus
 515 Tendons in Adults with Acquired Spasticity of the Hand." *J Bone Joint Surg Am* 69, no. 8
 516 (1987): 1127-32.
- 517 19. Braun, R. M., G. T. Vise, and B. Roper. "Preliminary Experience with Superficialis-to518 Profundus Tendon Transfer in the Hemiplegic Upper Extremity." *J Bone Joint Surg Am*519 56, no. 3 (1974): 466-72.
- 520 20. Bohannon, R. W., and M. B. Smith. "Interrater Reliability of a Modified Ashworth Scale
 521 of Muscle Spasticity." *Phys Ther* 67, no. 2 (1987): 206-7.
- Pandyan, A. D., G. R. Johnson, C. I. Price, R. H. Curless, M. P. Barnes, and H. Rodgers.
 "A Review of the Properties and Limitations of the Ashworth and Modified Ashworth
 Scales as Measures of Spasticity." *Clin Rehabil* 13, no. 5 (1999): 373-83.
- 525 22. Platz, T., C. Eickhof, G. Nuyens, and P. Vuadens. "Clinical Scales for the Assessment of
 526 Spasticity, Associated Phenomena, and Function: A Systematic Review of the Literature."
 527 Disabil Rehabil 27, no. 1-2 (2005): 7-18.
- Ansari, N. N., S. Naghdi, S. Hasson, M. H. Azarsa, and S. Azarnia. "The Modified Tardieu
 Scale for the Measurement of Elbow Flexor Spasticity in Adult Patients with Hemiplegia." *Brain Inj* 22, no. 13-14 (2008): 1007-12.
- 531 24. Katz, R. T., G. P. Rovai, C. Brait, and W. Z. Rymer. "Objective Quantification of Spastic
 532 Hypertonia: Correlation with Clinical Findings." *Arch Phys Med Rehabil* 73, no. 4 (1992):
 533 339-47.
- 534 25. Derungs, A., C. Schuster-Amft, and O. Amft. "Physical Activity Comparison between
 535 Body Sides in Hemiparetic Patients Using Wearable Motion Sensors in Free-Living and
 536 Therapy: A Case Series." *Front Bioeng Biotechnol* 6 (2018): 136.
- 537 26. Ezeugwu, V. E., and P. J. Manns. "Sleep Duration, Sedentary Behavior, Physical Activity,
 538 and Quality of Life after Inpatient Stroke Rehabilitation." *J Stroke Cerebrovasc Dis* 26, no.
 539 9 (2017): 2004-12.
- 540 27. Burridge, J. H., D. E. Wood, H. J. Hermens, G. E. Voerman, G. R. Johnson, F. van Wijck,
 541 T. Platz, M. Gregoric, R. Hitchcock, and A. D. Pandyan. "Theoretical and Methodological
 542 Considerations in the Measurement of Spasticity." *Disabil Rehabil* 27, no. 1-2 (2005): 69543 80.
- Lechner, H. E., A. Frotzler, and P. Eser. "Relationship between Self- and Clinically Rated
 Spasticity in Spinal Cord Injury." *Arch Phys Med Rehabil* 87, no. 1 (2006): 15-9.
- 546 29. Atzori, M., A. Gijsberts, C. Castellini, B. Caputo, A. G. M. Hager, S. Elsig, G. Giatsidis,
 547 F. Bassetto, and H. Muller. "Electromyography Data for Non-Invasive Naturally548 Controlled Robotic Hand Prostheses." *Scientific Data* 1 (2014).

- 549 30. Lu, Z., K. Y. Tong, X. Zhang, S. Li, and P. Zhou. "Myoelectric Pattern Recognition for
 550 Controlling a Robotic Hand: A Feasibility Study in Stroke." *IEEE Trans Biomed Eng* 66,
 551 no. 2 (2019): 365-72.
- 31. Ryser, F., T. Butzer, J. P. Held, O. Lambercy, and R. Gassert. "Fully Embedded
 Myoelectric Control for a Wearable Robotic Hand Orthosis." *IEEE Int Conf Rehabil Robot*2017 (2017): 615-21.
- S2. Cai, S., G. Li, X. Zhang, S. Huang, H. Zheng, K. Ma, and L. Xie. "Detecting Compensatory Movements of Stroke Survivors Using Pressure Distribution Data and Machine Learning Algorithms." *J Neuroeng Rehabil* 16, no. 1 (2019): 131.
- Jahanmiri-Nezhad, F., X. Y. Li, P. E. Barkhaus, W. Z. Rymer, and P. Zhou. "A Clinically
 Applicable Approach for Detecting Spontaneous Action Potential Spikes in Amyotrophic
 Lateral Sclerosis with a Linear Electrode Array." *Journal of Clinical Neurophysiology* 31,
 no. 1 (2014): 35-40.
- 562 34. Lonini, L., A. Dai, N. Shawen, T. Simuni, C. Poon, L. Shimanovich, M. Daeschler, R.
 563 Ghaffari, J. A. Rogers, and A. Jayaraman. "Wearable Sensors for Parkinson's Disease:
 564 Which Data Are Worth Collecting for Training Symptom Detection Models." *NPJ Digit*565 *Med* 1 (2018): 64.
- 566 35. Dobkin, B. H., and C. Martinez. "Wearable Sensors to Monitor, Enable Feedback, and
 567 Measure Outcomes of Activity and Practice." *Curr Neurol Neurosci Rep* 18, no. 12 (2018):
 568 87.
- 36. Voerman, G. E., J. F. Fleuren, L. A. Kallenberg, J. S. Rietman, G. J. Snoek, and H. J.
 Hermens. "Patient Ratings of Spasticity During Daily Activities Are Only Marginally
 Associated with Long-Term Surface Electromyography." *J Neurol Neurosurg Psychiatry*80, no. 2 (2009): 175-81.
- 37. Yamagami, M., K. M. Peters, I. Milovanovic, I. Kuang, Z. Yang, N. Lu, and K. M. Steele.
 37. "Assessment of Dry Epidermal Electrodes for Long-Term Electromyography
 575 Measurements." *Sensors (Basel)* 18, no. 4 (2018).
- 57638.De Luca, C. J. "The Use of Surface Electromyography in Biomechanics." Journal of577Applied Biomechanics 13, no. 2 (1997): 135-63.
- 39. Roy, S. H., G. De Luca, M. S. Cheng, A. Johansson, L. D. Gilmore, and C. J. De Luca.
 "Electro-Mechanical Stability of Surface Emg Sensors." *Medical & Biological Engineering & Computing* 45, no. 5 (2007): 447-57.
- 40. Beck, T. W., T. J. Housh, J. T. Cramer, M. H. Malek, M. Mielke, R. Hendrix, and J. P.
 Weir. "Electrode Shift and Normalization Reduce the Innervation Zone's Influence on Emg." *Medicine and Science in Sports and Exercise* 40, no. 7 (2008): 1314-22.
- McComas, A. J., R. E. Sica, A. R. Upton, and N. Aguilera. "Functional Changes in Motoneurones of Hemiparetic Patients." *J Neurol Neurosurg Psychiatry* 36, no. 2 (1973): 183-93.
- 587 42. Sica, R. E., and O. P. Sanz. "An Electrophysiological Study of the Functional Changes in the Spinal Motoneurones of Hemiparetic Patients." *Electromyogr Clin Neurophysiol* 16, no. 5 (1976): 419-31.
- 43. Garmirian, LRP, JPA Dewald, and AM. Acosta. "Reduction in Voluntary Activation of
 591 Elbow and Wrist Muscles in Individuals with Chronic Hemiparetic Stroke." *bioRxiv*592 689364 [Preprint] (2019).

- 593 44. Solnik, S., P. DeVita, P. Rider, B. Long, and T. Hortobagyi. "Teager-Kaiser Operator
 594 Improves the Accuracy of Emg Onset Detection Independent of Signal-to-Noise Ratio."
 595 Acta Bioeng Biomech 10, no. 2 (2008): 65-8.
- Solnik, S., P. Rider, K. Steinweg, P. DeVita, and T. Hortobagyi. "Teager-Kaiser Energy
 Operator Signal Conditioning Improves Emg Onset Detection." *Eur J Appl Physiol* 110, no. 3 (2010): 489-98.
- 59946.Li, X., and A. Aruin. "Muscle Activity Onset Time Detection Using Teager-Kaiser Energy600Operator." Conf Proc IEEE Eng Med Biol Soc 2005 (2005): 7549-52.
- 47. Binder-Markey BI, Murray WM, Dewald JP. . "Effects of Altered Neural Input and Botulinum Toxin on Finger and Wrist Passive Properties in Chronic Hemiparetic Stroke."
 603 medRxiv 19011312 [Preprint] (2020).
- 604 48. Schmit, B. D., J. P. Dewald, and W. Z. Rymer. "Stretch Reflex Adaptation in Elbow
 605 Flexors During Repeated Passive Movements in Unilateral Brain-Injured Patients." *Arch*606 *Phys Med Rehabil* 81, no. 3 (2000): 269-78.
- 49. Dai, C., N. L. Suresh, A. K. Suresh, W. Z. Rymer, and X. Hu. "Altered Motor Unit Discharge Coherence in Paretic Muscles of Stroke Survivors." *Front Neurol* 8 (2017): 202.
- 50. Hameed, H. K., W. Z. Wan Hasan, S. Shafie, S. A. Ahmad, H. Jaafar, and L. N. Inche Mat.
 "Investigating the Performance of an Amplitude-Independent Algorithm for Detecting the
 Hand Muscle Activity of Stroke Survivors." *J Med Eng Technol* 44, no. 3 (2020): 139-48.
- 612 51. Ebisuzaki, W. "A Method to Estimate the Statistical Significance of a Correlation When
 613 the Data Are Serially Correlated." *Journal of Climate* 10, no. 9 (1997): 2147-53.
- 52. Flansbjer, U. B., A. M. Holmback, D. Downham, C. Patten, and J. Lexell. "Reliability of
 Gait Performance Tests in Men and Women with Hemiparesis after Stroke." *J Rehabil Med*37, no. 2 (2005): 75-82.
- 53. Knorr, S., B. Brouwer, and S. J. Garland. "Validity of the Community Balance and
 Mobility Scale in Community-Dwelling Persons after Stroke." *Arch Phys Med Rehabil* 91,
 no. 6 (2010): 890-6.
- 54. Esquef, P. A. A., and L. W. P. Biscainho. "An Efficient Model-Based Multirate Method
 for Reconstruction of Audio Signals across Long Gaps." *Ieee Transactions on Audio Speech and Language Processing* 14, no. 4 (2006): 1391-400.
- 55. Mewett, D. T., H. Nazeran, and K. J. Reynolds. "Removing Power Line Noise from Recorded Emg." *Proceedings of the 23rd Annual International Conference of the Ieee Engineering in Medicine and Biology Society, Vols 1-4* 23 (2001): 2190-93.
- 626 56. Amma, C., T. Krings, J. Boer, and T. Schultz. "Advancing Muscle-Computer Interfaces
 627 with High-Density Electromyography." *Chi 2015: Proceedings of the 33rd Annual Chi*628 *Conference on Human Factors in Computing Systems* (2015): 929-38.
- 57. Konstantin, A., T. Yu, E. Le Carpentier, Y. Aoustin, and D. Farina. "Simulation of Motor
 Unit Action Potential Recordings from Intramuscular Multichannel Scanning Electrodes." *IEEE Trans Biomed Eng* 67, no. 7 (2020): 2005-14.
- 58. Koo, T. K., and M. Y. Li. "A Guideline of Selecting and Reporting Intraclass Correlation
 Coefficients for Reliability Research." *J Chiropr Med* 15, no. 2 (2016): 155-63.
- 634 59. Hiragami, S., Y. Inoue, and K. Harada. "Minimal Clinically Important Difference for the
 635 Fugl-Meyer Assessment of the Upper Extremity in Convalescent Stroke Patients with
 636 Moderate to Severe Hemiparesis." *J Phys Ther Sci* 31, no. 11 (2019): 917-21.
- 63760.Binder-Markey, B. I., W. M. Murray, and J. P. A. Dewald. "Passive Properties of the Wrist638and Fingers Following Chronic Hemiparetic Stroke: Interlimb Comparisons in Persons

- with and without a Clinical Treatment History That Includes Botulinum Neurotoxin." *Front Neurol* 12 (2021): 687624.
- 641 61. Baldwin, C., G. van Kessel, A. Phillips, and K. Johnston. "Accelerometry Shows Inpatients
 642 with Acute Medical or Surgical Conditions Spend Little Time Upright and Are Highly
 643 Sedentary: Systematic Review." *Phys Ther* 97, no. 11 (2017): 1044-65.
- 644 62. Ezeugwu, V. E., and P. J. Manns. "The Feasibility and Longitudinal Effects of a Home645 Based Sedentary Behavior Change Intervention after Stroke." *Arch Phys Med Rehabil* 99, no. 12 (2018): 2540-47.
- 647 63. Chang, S. H., G. E. Francisco, P. Zhou, W. Z. Rymer, and S. Li. "Spasticity, Weakness,
 648 Force Variability, and Sustained Spontaneous Motor Unit Discharges of Resting Spastic649 Paretic Biceps Brachii Muscles in Chronic Stroke." *Muscle Nerve* 48, no. 1 (2013): 85-92.
- 650 64. Liu, J., D. W. Ying, W. Z. Rymer, and P. Zhou. "Robust Muscle Activity Onset Detection
 651 Using an Unsupervised Electromyogram Learning Framework." *PLoS One* 10, no. 6
 652 (2015).
- 653
 65. Held, J. P. O., B. Klaassen, A. Eenhoorn, B. J. F. van Beijnum, J. H. Buurke, P. H. Veltink,
 654 and A. R. Luft. "Inertial Sensor Measurements of Upper-Limb Kinematics in Stroke
 655 Patients in Clinic and Home Environment." *Frontiers in Bioengineering and*656 *Biotechnology* 6 (2018).
- 657 66. Schwarz, A., M. M. C. Bhagubai, G. Wolterink, J. P. O. Held, A. R. Luft, and P. H. Veltink.
 658 "Assessment of Upper Limb Movement Impairments after Stroke Using Wearable Inertial
 659 Sensing." Sensors (Basel) 20, no. 17 (2020).
- 660 67. Van Meulen, F. B., B. Klaassen, J. Held, J. Reenalda, J. H. Buurke, B. J. F. Van Beijnum,
 661 A. Luft, and P. H. Veltink. "Objective Evaluation of the Quality of Movement in Daily
 662 Life after Stroke." *Frontiers in Bioengineering and Biotechnology* 3 (2016).
- 663 68. Karbasforoushan, H., J. Cohen-Adad, and J. P. A. Dewald. "Brainstem and Spinal Cord
 664 Mri Identifies Altered Sensorimotor Pathways Post-Stroke." *Nat Commun* 10, no. 1 (2019):
 665 3524.
- 666 69. McPherson, J. G., A. Chen, M. D. Ellis, J. Yao, C. J. Heckman, and J. P. A. Dewald.
 667 "Progressive Recruitment of Contralesional Cortico-Reticulospinal Pathways Drives 668 Motor Impairment Post Stroke." *J Physiol* 596, no. 7 (2018): 1211-25.
- 669 70. Owen, M., C. Ingo, and J. P. A. Dewald. "Upper Extremity Motor Impairments and
 670 Microstructural Changes in Bulbospinal Pathways in Chronic Hemiparetic Stroke." *Front*671 *Neurol* 8 (2017): 257.
- 672 71. Ellis, M. D., I. Schut, and J. P. A. Dewald. "Flexion Synergy Overshadows Flexor
 673 Spasticity During Reaching in Chronic Moderate to Severe Hemiparetic Stroke." *Clin*674 *Neurophysiol* 128, no. 7 (2017): 1308-14.
- 675 72. Lan, Y., J. Yao, and J. P. A. Dewald. "The Impact of Shoulder Abduction Loading on
 676 Volitional Hand Opening and Grasping in Chronic Hemiparetic Stroke." *Neurorehabil*677 *Neural Repair* 31, no. 6 (2017): 521-29.
- 578 73. Sukal, T. M., M. D. Ellis, and J. P. Dewald. "Shoulder Abduction-Induced Reductions in Reaching Work Area Following Hemiparetic Stroke: Neuroscientific Implications." *Exp Brain Res* 183, no. 2 (2007): 215-23.
- 74. Yang, Y., N. Sinha, R. Tian, N. Gurari, J. M. Drogos, and J. P. A. Dewald. "Quantifying
 Altered Neural Connectivity of the Stretch Reflex in Chronic Hemiparetic Stroke." *IEEE Trans Neural Syst Rehabil Eng* 28, no. 6 (2020): 1436-41.

- 684 75. Bhakta, B. B., J. A. Cozens, M. A. Chamberlain, and J. M. Bamford. "Quantifying
 685 Associated Reactions in the Paretic Arm in Stroke and Their Relationship to Spasticity."
 686 *Clin Rehabil* 15, no. 2 (2001): 195-206.
- 76. Taub, E., G. Uswatte, V. W. Mark, and D. M. Morris. "The Learned Nonuse Phenomenon:
 Implications for Rehabilitation." *Eura Medicophys* 42, no. 3 (2006): 241-56.
- Feldner, H. A., C. Papazian, K. Peters, and K. M. Steele. ""It's All Sort of Cool and Interesting...But What Do I Do with It?" A Qualitative Study of Stroke Survivors'
- 691 Perceptions of Surface Electromyography." *Front Neurol* 11 (2020): 1037.
- 692